Takeda Initiates TAK-536 Phase-III Clinical Trials In Japan

Takeda’ investigational compound, TAK-536 has entered into phase-III clinical trials in Japan. TAK-536 is a novel angiotensin receptor blocker (ARB) that is meant to lower blood pressure by inhibiting the action of the vasopressor hormone Angiotensin II.

TAK-536 is expected to show stronger anti-hypertensive action when compared to both Blopress and other existing ARBs, said the company.

Nancy Joseph-Ridge, General Manager of Pharmaceutical Development, Takeda, said: We will look forward to continuing the development of TAK-536, and to providing it as soon as possible to hypertensive patients in Japan in order to better control their blood pressure.”